← Leaderboards
Qi Cao
Methodist Hospital Research Institute
$5,501,009
Attributed
$7,023,524
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.2M · FY2017–25$2.5M$1.9M$1.3M$625K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,023,524 · 5
By mechanism
R01$7,023,524 · 5
Top collaborators
- Kaifu Chen2 shared
- Hengyao Niu2 shared
- Rendong Yang1 shared
Most similar at Methodist Hospital Research Institute
Same institution · by research overlap
- Keith Syson Chan$11,391,028
- Dan Theodorescu$43,145,134
- Stephen Tc Wong$23,111,474
- Kaifu Chen$6,629,635
Others in their field
Other Emerging Leaders on “Epigenetic Process”
- Michael-Christopher Keogh · Epicypher, Inc.$20,096,362
- Barbara Halina Braffett · George Washington University$9,972,097
- Ionut Bebu · George Washington University$9,972,097
- Jennifer Cohen Price · University Of California, San Francisco$9,197,178
- Scott Topper · Broad Institute, Inc.$8,965,812
- Ruchir Shah · Sciome, Llc$7,820,780
Research focus
Epigenetic ProcessLysineReportingModificationCancer InitiationPlayInsightProteinsNeoplasm MetastasisRegulationTranscriptPolycombMalignant NeoplasmsCancer TypeAffectComplexOncogenicHistonesMediatingNovel TherapeuticsKnock-DownMethylationHistone H3Cancer Etiology
Grant awards (16)
A novel role for EZH2 in A-to-I RNA editing in prostate cancer$655,269
R01 · FY2025 · CA · contact PI
Combinational targeting histone and RNA modifications in prostate cancer$570,096
R01 · FY2025 · CA · contact PI
A novel role for EZH2 in PARP regulation and PARPi-resistance in prostate cancer$567,198
R01 · FY2025 · CA · contact PI
A non-canonical role for EZH2 in rRNA methtlation$428,722
R01 · FY2025 · CA · contact PI
A novel role for EZH2 in A-to-I RNA editing in prostate cancer$670,269
R01 · FY2024 · CA · contact PI
A novel role for EZH2 in PARP regulation and PARPi-resistance in prostate cancer$582,198
R01 · FY2024 · CA · contact PI
A non-canonical role for EZH2 in rRNA methtlation$407,287
R01 · FY2024 · CA · contact PI
A non-canonical role for EZH2 in rRNA methtlation$420,147
R01 · FY2023 · CA · contact PI
A non-canonical role for EZH2 in rRNA methtlation$420,147
R01 · FY2022 · CA · contact PI
The inhibitory network between EZH2 and PARP1 in triple-negative breast cancer$141,652
R01 · FY2022 · CA · contact PI
A non-canonical role for EZH2 in rRNA methtlation$469,932
R01 · FY2021 · CA · contact PI
The inhibitory network between EZH2 and PARP1 in triple-negative breast cancer$227,779
R01 · FY2021 · CA · contact PI
The inhibitory network between EZH2 and PARP1 in triple-negative breast cancer$369,431
R01 · FY2020 · CA · contact PI
The inhibitory network between EZH2 and PARP1 in triple-negative breast cancer$358,347
R01 · FY2019 · CA · contact PI
The inhibitory network between EZH2 and PARP1 in triple-negative breast cancer$369,431
R01 · FY2018 · CA · contact PI
The inhibitory network between EZH2 and PARP1 in triple-negative breast cancer$365,619
R01 · FY2017 · CA · contact PI